, Volume 68, Issue 9, pp 1157–1167

Steroid-Refractory Severe Ulcerative Colitis

What are the Available Treatment Options?
Current Opinion


Approximately 15% of patients with ulcerative colitis will experience a severe episode requiring hospitalization. Although intravenous corticosteroids are the current first-line therapy for these patients, about 30% of patients do not respond to corticosteroids and require either an alternative anti-inflammatory agent or surgery. Ciclosporin has proven its efficacy in a number of controlled trials in this setting and is characterized by high early response rates. Patients who respond to ciclosporin and avoid colectomy are more likely to retain their colon if they bridge to immunomodulators in the medium term. Infliximab has also demonstrated efficacy in reducing early colectomy rates and longer term data are awaited. Other agents, such as tacrolimus and basiliximab, and leukocytapheresis, have been studied in small trials and may be alternative options. Key issues remain as to what should be first- and second-line therapies, when surgery should be undertaken, and the risk of switching between immunosuppressants in these critical patients.


  1. 1.
    Farmer RG, Easley KA, Rankin GB. Clinical patterns, natural history, and progression of ulcerative colitis: a long-term follow-up of 1116 patients. Dig Dis Sci 1993; 386: 1137–46CrossRefGoogle Scholar
  2. 2.
    Sonnenberg A. Time trends of mortality from Crohn’s disease and ulcerative colitis. Int J Epidemiol 2007; 364: 890–9CrossRefGoogle Scholar
  3. 3.
    Flatmark A, Fretheim B, Gjone E. Early colectomy in severe ulcerative colitis. Scand J Gastroenterol 1975; 104: 427–31Google Scholar
  4. 4.
    Truelove SC, Witts LJ. Cortisone in ulcerative colitis: final report on a therapeutic trial. Br Med J 1955; 24947: 1041–8CrossRefGoogle Scholar
  5. 5.
    Bernal I, Manosa M, Domenech E, et al. Predictors of clinical response to systemic steroids in active ulcerative colitis. Dig Dis Sci 2006; 518: 1434–8CrossRefGoogle Scholar
  6. 6.
    Jarnerot G, Rolny P, Sandberg-Gertzen H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology 1985; 895: 1005–13Google Scholar
  7. 7.
    Turner D, Walsh CM, Steinhart AH, et al. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol 2007; 51: 103–10CrossRefGoogle Scholar
  8. 8.
    Cooney RM, Warren BF, Altman DG, et al. Outcome measurement in clinical trials for ulcerative colitis: towards standardisation. Trials 2007; 8: 17PubMedCrossRefGoogle Scholar
  9. 9.
    Caprilli R, Vernia P, Colaneri O, et al. Blood pH: a test for assessment of severity in proctocolitis. Gut 1976; 1710: 763–9CrossRefGoogle Scholar
  10. 10.
    Travis SP, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut 1996; 386: 905–10CrossRefGoogle Scholar
  11. 11.
    Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study. N Engl J Med 1987; 31726: 1625–9CrossRefGoogle Scholar
  12. 12.
    Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004; 53 Suppl. 5: V1–16PubMedCrossRefGoogle Scholar
  13. 13.
    Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004; 997: 1371–85CrossRefGoogle Scholar
  14. 14.
    Benazzato L, D’Inca R, Grigoletto F, et al. Prognosis of severe attacks in ulcerative colitis: effect of intensive medical treatment. Dig Liver Dis 2004; 367: 461–6CrossRefGoogle Scholar
  15. 15.
    Chakravarty BJ. Predictors and the rate of medical treatment failure in ulcerative colitis. Am J Gastroenterol 1993; 886: 852–5Google Scholar
  16. 16.
    Ho GT, Mowat C, Goddard CJ, et al. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther 2004; 1910: 1079–87Google Scholar
  17. 17.
    Lindgren SC, Flood LM, Kilander AF, et al. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol 1998; 1010: 831–5CrossRefGoogle Scholar
  18. 18.
    Meyers S, Lerer PK, Feuer EJ, et al. Predicting the outcome of corticoid therapy for acute ulcerative colitis: results of a prospective, randomized, double-blind clinical trial. J Clin Gastroenterol 1987; 91: 50–4CrossRefGoogle Scholar
  19. 19.
    Sands BE, Tremaine WJ, Sandborn WJ, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001; 72: 83–8CrossRefGoogle Scholar
  20. 20.
    Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 33026: 1841–5CrossRefGoogle Scholar
  21. 21.
    Seo M, Okada M, Yao T, et al. Evaluation of the clinical course of acute attacks in patients with ulcerative colitis through the use of an activity index. J Gastroenterol 2002; 371: 29–34CrossRefGoogle Scholar
  22. 22.
    Flood L, Lofberg R, Stierna P, et al. Glucocorticoid receptor mRNA in patients with ulcerative colitis: a study of responders and nonresponders to glucocorticosteroid therapy. Inflamm Bowel Dis 2001; 73: 202–9CrossRefGoogle Scholar
  23. 23.
    Sambuelli AM, Negreira SM, Gil AH, et al. Multidrug resistance gene (MDR-1) expression in the colonic mucosa of patients with refractory ulcerative colitis. Acta Gastroenterol Latinoam 2006; 361: 23–32Google Scholar
  24. 24.
    Carbonnel F, Gargouri D, Lémann, et al. Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis. Aliment Pharmacol Ther 2000 mar; 14(3): 273–9PubMedCrossRefGoogle Scholar
  25. 25.
    Oshitani N, Kitano A, Fukushima R, et al. Predictive factors for the response of ulcerative colitis patients during the acute-phase treatment. Digestion 1990; 46(2): 107–13PubMedCrossRefGoogle Scholar
  26. 26.
    Borel JF, Kis ZL. The discovery and development of cyclosporine (Sandimmune). Transplant Proc 1991; 232: 1867–74Google Scholar
  27. 27.
    Kountouras J, Zavos C, Chatzopoulos D. Immunomodulatory benefits of cyclosporine A in inflammatory bowel disease. J Cell Mol Med 2004; 83: 317–28CrossRefGoogle Scholar
  28. 28.
    Ina K, Kusugami K, Shimada M, et al. Suppressive effects of cyclosporine A on neutrophils and T cells may be related to therapeutic benefits in patients with steroid-resistant ulcerative colitis. Inflamm Bowel Dis 2002; 81: 1–9CrossRefGoogle Scholar
  29. 29.
    D’Haens G, Lemmens L, Geboes K, et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001; 1206: 1323–9CrossRefGoogle Scholar
  30. 30.
    Van Assche G, D’Haens G, Noman M, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003; 1254: 1025–31CrossRefGoogle Scholar
  31. 31.
    Garcia-Lopez S, Gomollon-Garcia F, Perez-Gisbert J. Cyclosporine in the treatment of severe attack of ulcerative colitis: a systematic review. Gastroenterol Hepatol 2005; 2810: 607–14CrossRefGoogle Scholar
  32. 32.
    Durai D, Hawthorne AB. Review article: how and when to use ciclosporin in ulcerative colitis. Aliment Pharmacol Ther 2005; 2210: 907–16CrossRefGoogle Scholar
  33. 33.
    Pham CQ, Efros CB, Berardi RR. Cyclosporine for severe ulcerative colitis. Ann Pharmacother 2006; 401: 96–101Google Scholar
  34. 34.
    Shibolet O, Regushevskaya E, Brezis M, et al. Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev 2005; (1): CD004277Google Scholar
  35. 35.
    Actis GC, Aimo G, Priolo G, et al. Efficacy and efficiency of oral microemulsion cyclosporin versus intravenous and soft gelatin capsule cyclosporin in the treatment of severe steroid-refractory ulcerative colitis: an open-label retrospective trial. Inflamm Bowel Dis 1998; 44: 276–9Google Scholar
  36. 36.
    Actis GC, Lagget M, Rizzetto M, et al. Long-term efficacy of oral microemulsion cyclosporin for refractory ulcerative colitis. Minerva Med 2004; 951: 65–70Google Scholar
  37. 37.
    Navazo L, Salata H, Morales S, et al. Oral microemulsion cyclosporine in the treatment of steroid-refractory attacks of ulcerative and indeterminate colitis. Scand J Gastroenterol 2001; 366: 610–4CrossRefGoogle Scholar
  38. 38.
    Ortiz V, Nos P, Aguilera V, et al. Cyclosporin in an oral microemulsion as the initial treatment of corticoid-refractory ulcerative colitis [in Spanish]. Gastroenterol Hepatol 2000; 233: 120–2Google Scholar
  39. 39.
    Weber A, Fein F, Koch S, et al. Treatment of ulcerative colitis refractory to steroid therapy by oral microemulsion cyclosporine (Neoral). Inflamm Bowel Dis 2006; 1212: 1131–5CrossRefGoogle Scholar
  40. 40.
    Cacheux W, Seksik P, Lemann M, et al. Predictive factors of response to cyclosporine in steroid-refractory ulcerative colitis. Am J Gastroenterol 2008; 103(3): 637–42PubMedCrossRefGoogle Scholar
  41. 41.
    Daniel F, Loriot MA, Seksik P, et al. Multidrug resistance gene-1 polymorphisms and resistance to cyclosporine A in patients with steroid resistant ulcerative colitis. Inflamm Bowel Dis 2007; 131: 19–23CrossRefGoogle Scholar
  42. 42.
    Rowe FA, Walker JH, Karp LC, et al. Factors predictive of response to cyclosporin treatment for severe, steroid-resistant ulcerative colitis. Am J Gastroenterol 2000; 958: 2000–8CrossRefGoogle Scholar
  43. 43.
    Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol 1999; 946: 1587–92CrossRefGoogle Scholar
  44. 44.
    de Saussure P, Soravia C, Morel P, et al. Low-dose oral microemulsion ciclosporin for severe, refractory ulcerative colitis. Aliment Pharmacol Ther 2005; 223: 203–8CrossRefGoogle Scholar
  45. 45.
    Haslam N, Hearing SD, Probert CS. Audit of cyclosporin use in inflammatory bowel disease: limited benefits, numerous side-effects. Eur J Gastroenterol Hepatol 2000; 126: 657–60CrossRefGoogle Scholar
  46. 46.
    Stack WA, Long RG, Hawkey CJ. Short-and long-term outcome of patients treated with cyclosporin for severe acute ulcerative colitis. Aliment Pharmacol Ther 1998; 1210: 973–8CrossRefGoogle Scholar
  47. 47.
    Arts J, D’Haens G, Zeegers M, et al. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis 2004; 102: 73–8CrossRefGoogle Scholar
  48. 48.
    de Groen PC, Aksamit AJ, Rakela J, et al. Central nervous system toxicity after liver transplantation: the role of cyclosporine and cholesterol. N Engl J Med 1987; 31714: 861–6CrossRefGoogle Scholar
  49. 49.
    Vogt DP, Lederman RJ, Carey WD, et al. Neurologic complications of liver transplantation. Transplantation 1988; 456: 1057–61CrossRefGoogle Scholar
  50. 50.
    Campbell S, Ghosh S. Combination immunomodulatory therapy with cyclosporine and azathioprine in corticosteroid-resistant severe ulcerative colitis: the Edinburgh experience of outcome. Dig Liver Dis 2003; 358: 546–51CrossRefGoogle Scholar
  51. 51.
    Campbell S, Travis S, Jewell D. Ciclosporin use in acute ulcerative colitis: a long-term experience. Eur J Gastroenterol Hepatol 2005; 171: 79–84CrossRefGoogle Scholar
  52. 52.
    Domenech E, Garcia-Planella E, Bernal I, et al. Azathioprine without oral ciclosporin in the long-term maintenance of remission induced by intravenous ciclosporin in severe, steroid-refractory ulcerative colitis. Aliment Pharmacol Ther 2002; 1612: 2061–5CrossRefGoogle Scholar
  53. 53.
    Moskovitz DN, Van Assche G, Maenhout B, et al. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol 2006; 46: 760–5CrossRefGoogle Scholar
  54. 54.
    Cohen RD, Brodsky AL, Hanauer SB. A comparison of the quality of life in patients with severe ulcerative colitis after total colectomy versus medical treatment with intravenous cyclosporin. Inflamm Bowel Dis 1999; 51: 1–10CrossRefGoogle Scholar
  55. 55.
    Braat H, Peppelenbosch MP, Hommes DW. Immunology of Crohn’s disease. Ann N Y Acad Sci 2006; 107: 2135–54Google Scholar
  56. 56.
    Aspalter RM, Eibl MM, Wolf HM. Regulation of TCR-mediated T cell activation by TNF-RII. J Leukoc Biol 2003; 744: 572–82CrossRefGoogle Scholar
  57. 57.
    Seitz C, Muller P, Krieg RC, et al. A novel p75TNF receptor isoform mediating NFkappa B activation. J Biol Chem 2001; 27622: 19390–5CrossRefGoogle Scholar
  58. 58.
    Ina K, Itoh J, Fukushima K, et al. Resistance of Crohn’s disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance. J Immunol 1999; 1632: 1081–90Google Scholar
  59. 59.
    Hassan C, Ierardi E, Burattini O, et al. Tumour necrosis factor alpha down-regulation parallels inflammatory regression in ulcerative colitis patients treated with infliximab. Dig Liver Dis 2007; 399: 811–7CrossRefGoogle Scholar
  60. 60.
    Probert CS, Hearing SD, Schreiber S, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003; 527: 998–1002CrossRefGoogle Scholar
  61. 61.
    Järnerot G, Hertevig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomised, placebo-controlled study. Gastroenterology 2005 Jun; 128(7): 1805–11PubMedCrossRefGoogle Scholar
  62. 62.
    Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 35323: 2462–76CrossRefGoogle Scholar
  63. 63.
    Gisbert JP, Gonzalez-Lama Y, Mate J. Systematic review: infliximab therapy in ulcerative colitis. Aliment Pharmacol Ther 2007; 251: 19–37Google Scholar
  64. 64.
    Bermejo F, Lopez-Sanroman A, Hinojosa J, et al. Infliximab induces clinical, endoscopic and histological responses in refractory ulcerative colitis. Rev Esp Enferm Dig 2004; 962: 94–101Google Scholar
  65. 65.
    Mamula P, Markowitz JE, Brown KA, et al. Infliximab as a novel therapy for pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr 2002; 343: 307–11CrossRefGoogle Scholar
  66. 66.
    Mamula P, Markowitz JE, Cohen LJ, et al. Infliximab in pediatric ulcerative colitis: two-year follow-up. J Pediatr Gastroenterol Nutr 2004; 383: 298–301CrossRefGoogle Scholar
  67. 67.
    Serrano MS, Schmidt-Sommerfeld E, Kilbaugh TJ, et al. Use of infliximab in pediatric patients with inflammatory bowel disease. Ann Pharmacother 2001; 357-8: 823–8CrossRefGoogle Scholar
  68. 68.
    Jakobovits SL, Jewell DP, Travis SP. Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006. Aliment Pharmacol Ther 2007; 259: 1055–60CrossRefGoogle Scholar
  69. 69.
    Kohn A, Daperno M, Armuzzi A, et al. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up. Aliment Pharmacol Ther 2007; 265: 747–56CrossRefGoogle Scholar
  70. 70.
    Schluender SJ, Ippoliti A, Dubinsky M, et al. Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis? Dis Colon Rectum 2007; 5011: 1747–53CrossRefGoogle Scholar
  71. 71.
    Maser E, Deconda D, Lichtiger S, et al. Cyclosporine (CsA) and infliximab (Inf) as acute salvage therapies for each other, in severe steroid refractory ulcerative colitis (UC) [abstract]. Gastroenterology 2007; 1324: A–180Google Scholar
  72. 72.
    Creed TJ, Norman MR, Probert CS, et al. Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment Pharmacol Ther 2003; 181: 65–75CrossRefGoogle Scholar
  73. 73.
    Creed TJ, Probert CS, Norman MN, et al. Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease. Aliment Pharmacol Ther 2006; 2310: 1435–42CrossRefGoogle Scholar
  74. 74.
    Plevy S, Salzberg B, Van Assche G, et al. A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. Gastroenterology 2007; 1335: 1414–22CrossRefGoogle Scholar
  75. 75.
    Aoki H, Nakamura K, Yoshimatsu Y, et al. Adacolumn selective leukocyte adsorption apheresis in patients with active ulcerative colitis: clinical efficacy, effects on plasma IL-8, and expression of Toll-like receptor 2 on granulocytes. Dig Dis Sci 2007; 526: 1427–33CrossRefGoogle Scholar
  76. 76.
    Barta Z, Toth L, Zeher M. Pulse cyclophosphamide therapy for inflammatory bowel disease. World J Gastroenterol 2006; 128: 1278–80Google Scholar
  77. 77.
    Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005; 35224: 2499–507CrossRefGoogle Scholar
  78. 78.
    Fellermann K, Tanko Z, Herrlinger KR, et al. Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm Bowel Dis 2002; 85: 317–24CrossRefGoogle Scholar
  79. 79.
    Lazzerini M, Martelossi S, Marchetti F, et al. Efficacy and safety of thalidomide in children and young adults with intractable inflammatory bowel disease: long-term results. Aliment Pharmacol Ther 2007; 254: 419–27CrossRefGoogle Scholar
  80. 80.
    Musch E, Andus T, Malek M, et al. Successful treatment of steroid refractory active ulcerative colitis with natural interferon-beta: an open long-term trial. Z Gastroenterol 2007; 4512: 1235–40CrossRefGoogle Scholar
  81. 81.
    Stremmel W, Ehehalt R, Autschbach F, et al. Phosphatidylcholine for steroid-refractory chronic ulcerative colitis: a randomized trial. Ann Intern Med 2007; 1479: 603–10Google Scholar
  82. 82.
    Metcalf AM. Elective and emergent operative management of ulcerative colitis. Surg Clin North Am 2007; 873: 633–41CrossRefGoogle Scholar
  83. 83.
    Lichtenstein GR, Cohen R, Yamashita B, et al. Quality of life after proctocolectomy with ileoanal anastomosis for patients with ulcerative colitis. J Clin Gastroenterol 2006; 408: 669–77CrossRefGoogle Scholar
  84. 84.
    Hahnloser D, Pemberton JH, Wolff BG, et al. Results at up to 20 years after ileal pouch-anal anastomosis for chronic ulcerative colitis. Br J Surg 2007; 943: 333–40CrossRefGoogle Scholar
  85. 85.
    Meagher AP, Farouk R, Dozois RR, et al. J ileal pouch-anal anastomosis for chronic ulcerative colitis: complications and long-term outcome in 1310 patients. Br J Surg 1998; 856: 800–3CrossRefGoogle Scholar
  86. 86.
    Mahadevan U, Sandborn WJ. Diagnosis and management of pouchitis. Gastroenterology 2003; 1246: 1636–50CrossRefGoogle Scholar
  87. 87.
    Waljee A, Waljee J, Morris AM, et al. Threefold increased risk of infertility: a meta-analysis of infertility after ileal pouch anal anastomosis in ulcerative colitis. Gut 2006; 5511: 1575–80CrossRefGoogle Scholar
  88. 88.
    Wikland M, Jansson I, Asztely M, et al. Gynaecological problems related to anatomical changes after conventional proctocolectomy and ileostomy. Int J Colorectal Dis 1990; 51: 49–52CrossRefGoogle Scholar
  89. 89.
    Hyde GM, Jewell DP, Kettlewell MG, et al. Cyclosporin for severe ulcerative colitis does not increase the rate of perioperative complications. Dis Colon Rectum 2001; 4410: 1436–40CrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  1. 1.Harvard Medical School, Center for Inflammatory Bowel Disease, Gastroenterology, Rose 1 / EastBeth Israel Deaconess Medical CenterBostonUSA

Personalised recommendations